| Approval hurdles rising while budgets shrink—AI and data-driven strategies seen as critical
| JNPMEDI introduces AI-driven consulting platform with FDA expertise to support global expansion
The U.S. Food and Drug Administration (FDA). Photo: Yonhap News, REUTERS / Andrew Kelly, File Photo.
The number of new drugs approved by the U.S. Food and Drug Administration (FDA) dropped sharply in the first half of 2025, posing growing challenges for Korean pharmaceutical and biotech companies seeking to enter the U.S. market. Amid rapidly shifting FDA regulatory trends, solutions that can deliver timely and accurate regulatory intelligence are gaining attention as essential tools for U.S. expansion.
According to a report by Eugene Investment & Securities released on the 5th, the FDA cleared just 16 new drugs in the first half, down 24% from a year earlier and well below the five-year average of 23. Analysts attribute the decline partly to global pharma shifting its focus to indication expansions following a wave of new drug launches, but also to staff reductions following a broad FDA restructuring under the Trump administration.
Budget pressures are compounding the issue. The administration has proposed cutting the FDA’s 2026 budget by 5.5% to USD 6.8 billion. The Congressional Budget Office projects such cuts could lead to fewer drug approvals over the coming decades. Meanwhile, the FDA is deploying its in-house AI program “ELSA” and phasing out animal testing, further increasing unpredictability for drug development and commercialization.
Despite the uncertainty, the U.S. remains the world’s largest pharmaceutical market and a critical gateway to global expansion. Korean firms, encouraged by recent successes, are stepping up efforts to enter the market. For companies aspiring to become “the next LECLAZA,” specialized solutions that can quickly interpret and respond to changes in the U.S. regulatory environment are now becoming indispensable.
One such player is JNPMEDI, which combines AI-powered clinical trial consulting with deep FDA regulatory expertise. Its flagship platform, the Maven Clinical Cloud, is an end-to-end system that integrates clinical trial planning, execution, and data analysis to optimize the entire clinical development process.
A key solution, Maven Converter, transforms raw clinical trial data into the CDISC-standard SDTM format, generating submission-ready datasets that enable faster and more accurate regulatory compliance. This helps reduce errors and delays in FDA submissions while strengthening alignment with international data standards.
JNPMEDI’s FDA Expert Solution is staffed with highly experienced professionals, including a Chief Medical Officer (CMO), U.S.-licensed pharmacists, and attorneys who advise on regulatory strategy, partnerships, and market entry. With deep expertise in U.S. regulatory processes, they play a central role in helping companies navigate complex approval pathways and build sustainable global expansion strategies.
By leveraging this integrated approach, companies can significantly reduce the time and cost burdens associated with FDA approvals, reimbursement preparation, and clinical trial operations, allowing them to focus more fully on their core R&D activities.
A JNPMEDI spokesperson said the firm provides tailored consulting optimized for each company’s characteristics and development stage, from pharmaceutical and biotech firms to medical device companies, adding: “From building FDA-compliant data management systems to guiding Pre-IND meetings, we help accelerate our clients’ entry into global clinical development and commercialization.”
✔️ Read the original article: Click
| Approval hurdles rising while budgets shrink—AI and data-driven strategies seen as critical
| JNPMEDI introduces AI-driven consulting platform with FDA expertise to support global expansion
The number of new drugs approved by the U.S. Food and Drug Administration (FDA) dropped sharply in the first half of 2025, posing growing challenges for Korean pharmaceutical and biotech companies seeking to enter the U.S. market. Amid rapidly shifting FDA regulatory trends, solutions that can deliver timely and accurate regulatory intelligence are gaining attention as essential tools for U.S. expansion.
According to a report by Eugene Investment & Securities released on the 5th, the FDA cleared just 16 new drugs in the first half, down 24% from a year earlier and well below the five-year average of 23. Analysts attribute the decline partly to global pharma shifting its focus to indication expansions following a wave of new drug launches, but also to staff reductions following a broad FDA restructuring under the Trump administration.
Budget pressures are compounding the issue. The administration has proposed cutting the FDA’s 2026 budget by 5.5% to USD 6.8 billion. The Congressional Budget Office projects such cuts could lead to fewer drug approvals over the coming decades. Meanwhile, the FDA is deploying its in-house AI program “ELSA” and phasing out animal testing, further increasing unpredictability for drug development and commercialization.
Despite the uncertainty, the U.S. remains the world’s largest pharmaceutical market and a critical gateway to global expansion. Korean firms, encouraged by recent successes, are stepping up efforts to enter the market. For companies aspiring to become “the next LECLAZA,” specialized solutions that can quickly interpret and respond to changes in the U.S. regulatory environment are now becoming indispensable.
One such player is JNPMEDI, which combines AI-powered clinical trial consulting with deep FDA regulatory expertise. Its flagship platform, the Maven Clinical Cloud, is an end-to-end system that integrates clinical trial planning, execution, and data analysis to optimize the entire clinical development process.
A key solution, Maven Converter, transforms raw clinical trial data into the CDISC-standard SDTM format, generating submission-ready datasets that enable faster and more accurate regulatory compliance. This helps reduce errors and delays in FDA submissions while strengthening alignment with international data standards.
JNPMEDI’s FDA Expert Solution is staffed with highly experienced professionals, including a Chief Medical Officer (CMO), U.S.-licensed pharmacists, and attorneys who advise on regulatory strategy, partnerships, and market entry. With deep expertise in U.S. regulatory processes, they play a central role in helping companies navigate complex approval pathways and build sustainable global expansion strategies.
By leveraging this integrated approach, companies can significantly reduce the time and cost burdens associated with FDA approvals, reimbursement preparation, and clinical trial operations, allowing them to focus more fully on their core R&D activities.
A JNPMEDI spokesperson said the firm provides tailored consulting optimized for each company’s characteristics and development stage, from pharmaceutical and biotech firms to medical device companies, adding: “From building FDA-compliant data management systems to guiding Pre-IND meetings, we help accelerate our clients’ entry into global clinical development and commercialization.”
✔️ Read the original article: Click